VITamin D OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

维生素 D OmegA-3 TriaL (VITAL)：骨折、维生素 D 和遗传标记

• 批准号: 10402353
• 负责人: MERYL Susan LEBOFF
• 金额: $ 53.68万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10402353
• 关键词: 25-hydroxyvitamin D; Affect; African American population; Albumins; Ancillary Study; Benefits and Risks; Binding Proteins; Biological Markers; Blood specimen; Body mass index; Bone Density; Bone Diseases; Calcium; Candidate Disease Gene; Cardiovascular Diseases; Cholecalciferol; Clinical; Conflict (Psychology); Consensus; Consent; Cross-Sectional Studies; DNA; Data; Dose; Elderly; Ethnic Origin; Ethnic group; Femoral Fractures; Fish Oils; Fracture; Funding; Genes; Genetic Markers; Genetic Variation; Genetic study; Genotype; Goals; Guidelines; High Prevalence; Hip Fractures; Homeostasis; Hormones; Institute of Medicine (U.S.); Knowledge; Malignant Neoplasms; Measurement; Measures; Medical Records; Metabolism; Observational Study; Omega-3 Fatty Acids; Osteoporosis; Outcome; Parents; Participant; Pathway interactions; Placebos; Population; Prevention; Prevention trial; Primary Cancer Prevention; Primary Prevention; Proteins; Public Health; Questionnaires; Race; Randomized; Randomized Controlled Trials; Reporting; Resources; Risk; Risk Factors; Role; Sampling; Serum; Supplementation; Technology; Testing; Time; Uncertain Risk; United States National Institutes of Health; Variant; Vitamin D; Vitamin D Deficiency; Vitamin D supplementation; Vitamin D-Binding Protein; Woman; absorption; adjudication; aged; antibody test; arm; biomarker performance; bone; bone health; clinical risk; cohort; cost; cost efficient; design; follow-up; fracture risk; genetic variant; high risk; improved; interest; men; osteoporosis with pathological fracture; prevent; radiological imaging; receptor function; sex; systematic review; treatment duration; whole genome

ABSTRACT There are high prevalences of osteoporotic fractures and vitamin D deficiency in the U.S., especially among older adults. Although vitamin D supplements are widely used to improve bone health, evidence for a role of supplemental vitamin D alone in reducing fractures is lacking. While the serum 25-hydroxyvitamin D [25(OH)D] level is considered the best analyte to assess vitamin D status, currently there is no consensus on the optimal circulating total 25(OH)D concentration for bone. While, like many hormones, vitamin D circulates bound to proteins, the relative importance of free 25(OH)D (FVD) or bioavailable 25(OH)D levels on fracture risk is not known. New advances in technology make it possible to directly measure the biologically active, FVD level. Results from recent observational studies on whether FVD and/or bioavailable 25(OH)D are more strongly associated than total 25(OH)D levels with calcium homeostasis and bone mineral density (BMD) are inconsistent. In addition, there are no data from large, randomized controlled trials on whether bioavailable 25(OH)D and/or FVD vs. total 25(OH)D levels or gene variations in vitamin D-related pathways modify effects of supplemental vitamin D on fractures and changes in BMD. To fill gaps in knowledge, we propose an ancillary study to the large, NIH-sponsored, randomized, controlled VITamin D and OmegA-3 TriaL (VITAL) that is testing effects of supplemental vitamin D3 (cholecalciferol, 2000 IU/d), and/or omega-3 fatty acids (fish oil, 1 g/d) in the primary prevention of cancer and cardiovascular disease in 25,874 U.S. men (aged ≥50) and women (aged ≥55), including 5,107 African Americans. The proposed ancillary study will definitively determine whether supplemental, high-dose, vitamin D3 alone reduces incident total, non-vertebral and hip fractures by extending adjudication of fractures to the full 5 years of treatment in 25,874 VITAL participants nationwide. The proposed studies will also rigorously test whether concentrations of bioavailable 25(OH)D and/or FVD are more strongly associated with changes in BMD and incident fractures than total 25(OH)D levels; and whether these vitamin D biomarkers and genetic variants in vitamin D-related pathways modify effects of supplemental vitamin D on BMD and fracture risk. For each of the proposed aims, we will assess whether results vary by (a) sex, (b) race/ethnicity, and (c) BMI. Key VITAL resources will be leveraged at no additional cost to the proposed studies including: blood samples and BMD measurements (at baseline and follow-up), extensive data on changes in 25(OH)D levels over time (in the treatment vs. placebo arms), measures of calcium homeostasis, information on clinical risk factors, and extracted DNA. This proposal provides a unique and cost- efficient opportunity to generate important positive or informative negative results about effects of supplemental vitamin D3 alone on fracture risk, while also elucidating the relative importance of vitamin D biomarkers and genetic variations in vitamin D-related pathways on bone. Findings from the proposed ancillary study have the potential for major clinical as well as public health impact for both men and women in the U.S.

摘要 在美国，骨质疏松性骨折和维生素D缺乏症的发病率很高，特别是在 上了年纪的人。虽然维生素D补充剂被广泛用于改善骨骼健康，但有证据表明维生素D的作用 仅补充维生素D在减少骨折方面是缺乏的。而血清25-羟基维生素D[25(OH)D] 水平被认为是评估维生素D状况的最佳分析物，目前对最佳水平还没有达成共识 骨循环总25(OH)D浓度。然而，像许多荷尔蒙一样，维生素D循环一定会 蛋白质，游离的25(OH)D(FVD)或生物可利用的25(OH)D水平对骨折风险的相对重要性不是 为人所知。新技术的进步使直接测量生物活性的FVD水平成为可能。 最近关于FVD和/或生物可利用25(OH)D是否更强的观察研究结果 与钙稳态和骨密度(BMD)相关的总25(OH)D水平是 前后不一致。此外，没有来自大型随机对照试验的关于生物利用度的数据 25(OH)D和/或FVD与总的25(OH)D水平或维生素D相关途径中的基因变异改变效应 补充维生素D对骨折和骨密度变化的影响。为了填补知识空白，我们提出了一种 由美国国立卫生研究院赞助的大型随机对照维生素D和omega-3试验的辅助研究(VITAL) 这是测试补充维生素D3(胆钙化醇，2000IU/d)和/或omega-3脂肪酸(鱼)的效果 石油，1g/d)在25,874名美国男性(≥50岁)和 妇女(55岁，≥)，包括5,107名非裔美国人。拟议的辅助研究将最终确定 补充大剂量维生素D3是否能减少总的、非脊椎和髋部骨折的发生率 在全国25,874名重要参与者中，将骨折的裁决延长至整整5年的治疗。这个 拟议的研究还将严格测试生物可用25(OH)D和/或FVD的浓度是否 与总的25(OH)D水平相比，与BMD的变化和发生的骨折的相关性更强； 这些维生素D生物标志物和维生素D相关途径中的遗传变异可以改变补充剂的效果 维生素D对骨密度和骨折风险的影响。就每项建议的目标而言，我们会评估结果会否因(A) 性别，(B)种族/民族，和(C)BMI。关键关键资源将在不增加成本的情况下得到利用 拟议的研究包括：血样和骨密度测量(基线和后续)，广泛 25(OH)D水平随时间变化的数据(在治疗组和安慰剂组中)，钙的测量 动态平衡，临床风险因素的信息，以及提取的DNA。这项建议提供了独特的成本- 有效的机会产生关于补充的影响的重要的积极或信息性的负面结果 维生素D3单独对骨折风险的影响，同时也阐明了维生素D生物标志物和 骨骼上维生素D相关途径的遗传变异。拟议附属研究的结果包括 可能对美国男性和女性的临床和公共健康产生重大影响。

项目成果

VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL).

• DOI: 10.1016/j.cct.2015.01.007
• 发表时间: 2015-03
• 期刊: Contemporary clinical trials
• 影响因子: 2.2
• 作者: LeBoff MS;Yue AY;Copeland T;Cook NR;Buring JE;Manson JE
• 通讯作者: Manson JE

Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults.

• DOI: 10.1056/nejmoa2202106
• 发表时间: 2022-07-28
• 期刊: The New England journal of medicine

Accounting for Surgical Confounding Factors Affecting Dual-Energy X-ray Absorptiometry in a Large Clinical Trial.

• DOI: 10.1016/j.jocd.2021.06.002
• 发表时间: 2022-04
• 期刊: Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
• 作者: Donlon CM;Chou SH;Yu CY;LeBoff MS
• 通讯作者: LeBoff MS

The clinician's guide to prevention and treatment of osteoporosis.

• DOI: 10.1007/s00198-021-05900-y
• 发表时间: 2022-10
• 期刊: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial.

• DOI: 10.1001/jamanetworkopen.2022.31206
• 发表时间: 2022-09-01
• 期刊: JAMA NETWORK OPEN
• 影响因子: 13.8
• 作者: Orkaby, Ariela R.;Dushkes, Rimma;Ward, Rachel;Djousse, Luc;Buring, Julie E.;Lee, I-Min;Cook, Nancy R.;LeBoff, Meryl S.;Okereke, Olivia, I;Copeland, Trisha;Manson, JoAnn E.
• 通讯作者: Manson, JoAnn E.